Whitehawk Therapeutics, Inc. (3350)

Overview

Whitehawk Therapeutics, Inc. is an oncology biotechnology company dedicated to the discovery and development of antibody-drug conjugate (ADC) therapies aimed at treating cancer. The company’s primary goal is to leverage next-generation ADC platform technologies engineered for enhanced stability and an improved therapeutic index, targeting patients suffering from challenging, treatment-resistant tumors. Its research and development efforts focus on a promising pipeline of three ADC assets, specifically designed to target clinically validated proteins that are widely expressed across various tumor types, with a particular emphasis on lung and gynecological cancers. By utilizing advanced insights into tumor biology, Whitehawk Therapeutics aims to optimize the dosing and delivery of its therapies, addressing the limitations found in earlier ADC approaches. The company, formerly known as Aadi Bioscience, rebranded in March 2025, reflecting its renewed commitment to innovation in cancer treatment solutions. Headquartered in Morristown, New Jersey, Whitehawk Therapeutics plays a significant role within the healthcare and biotechnology sectors, acting as a key contributor to the advancement of targeted cancer therapies for patients with substantial unmet medical needs.

Products and Services

• Antibody-Drug Conjugate (ADC) Therapies

  Whitehawk Therapeutics specializes in the development of ADC therapies that combine the targeted delivery of cytotoxic agents to cancer cells while minimizing damage to surrounding healthy tissues. The company’s ADC assets are based on advanced platform technologies designed for greater stability and a higher therapeutic index, aiming to improve patient outcomes.

• Cancer Pipeline

  The company’s pipeline includes three promising ADC assets that target proteins validated in clinical settings. These assets are strategically focused on treating lung and gynecological cancers, addressing the needs of patients with treatment-resistant tumors by providing tailored therapeutic approaches.

• Next-Generation ADC Platform

  Whitehawk Therapeutics employs next-generation ADC platform technologies that enhance the reliability and efficacy of its therapies. These technologies are designed to ensure better stability of drug conjugates, thereby improving their performance and safety profiles in cancer treatment.

• Advanced Tumor Biology Insights

  Utilizing cutting-edge research in tumor biology, Whitehawk Therapeutics is able to more effectively dose and deliver its ADC therapies. This scientific approach aims to navigate the complexities associated with cancer treatment, particularly with challenging tumor types that have previously been deemed treatment-resistant.